Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CCL22 is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Additionally we are shipping CCL22 Kits (97) and CCL22 Proteins (67) and many more products for this protein.
Showing 10 out of 209 products:
Human Monoclonal CCL22 Primary Antibody for FACS - ABIN4896920
Mizukami, Kono, Kawaguchi, Akaike, Kamimura, Sugai, Fujii: CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. in International journal of cancer 2008
Show all 3 references for 4896920
Human Polyclonal CCL22 Primary Antibody for ELISA, WB - ABIN1534673
Mosser, Douar, Sarde, Kioschis, Feil, Moser, Poustka, Mandel, Aubourg: Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. in Nature 1993
Show all 2 references for 1534673
Human Monoclonal CCL22 Primary Antibody for IHC, WB - ABIN2674331
Musolino, Gong, Snyder, Jimenez, Lok, Lo, Moser, Grabowski, Frosch, Eichler: Brain endothelial dysfunction in cerebral adrenoleukodystrophy. in Brain : a journal of neurology 2015
Human Polyclonal CCL22 Primary Antibody for ELISA, WB - ABIN409112
Höftberger, Kunze, Weinhofer, Aboul-Enein, Voigtländer, Oezen, Amann, Bernheimer, Budka, Berger: Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy. in Neurobiology of disease 2007
CCL22 plays an important role in supporting gastric cancer development presumably by increasing the percentage of regulatory T cells in the tumor microenvironments. CCL22 levels in sera have a predictive value for gastric cancer peritoneal metastasis and the early recurrence.
The CCL22-mediated enhancement of antitumor responses is however not due to conversion, but rather to redirection of existing regulatory T cells to the site of cutaneous overexpression.
CCL22 and IL-37 with a co-localization in non-small cell lung cancer A549 cells inhibited the proliferation and epithelial-mesenchymal transition process
Data suggest that Th1 (show TH1L Antibodies) (IFN-gamma (show IFNG Antibodies)-inducible protein-10 IP-10/CXCL10 (show CXCL10 Antibodies)) and Th2 (thymus and activation regulated chemokine TARC/CCL17 (show CCL17 Antibodies)) and (macrophage derived chemokine MDC/CCL22) cooperatively play a role in the development of ankylosing spondylitis (AS).
Our results demonstrate that CCL22 is expressed in human placenta. Decidual expression was only observed in miscarriage conditions and correlates with Treg infiltration.
Distinctive Treg associated CCR4 (show CCR4 Antibodies)-CCL22 expression profile with altered frequency of Th17/Treg cell in the immunopathogenesis of Pemphigus Vulgaris (show DSG3 Antibodies).
type I IFN blocks the regulatory T cell-attracting chemokine (show CCL1 Antibodies) CCL22 and thus helps limit the recruitment of regulatory T cells to tumors
First-episode psychosis patients had higher serum CCL22, which decreased substantially following antipsychotic treatment.
Elevated levels of CCL22 found in the ascites could create a chemokine (show CCL1 Antibodies) gradient aiding in Treg cells migration. Increased Tregs percentage in the local microenvironment of ovarian cancer might be an important mechanism of immunosuppression.
Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histology, grade and IDH (show IDH1 Antibodies) mutation status. CCL22 should be considered a marker of immune status with potential prognostic value
Intratumoral administration of anti-CCL22 antibody inhibited B16F10 melanoma growth.
this study shows that intravenous injection of apoptotic cells induces a subsequent increase in CCL22 expression and CCR4 (show CCR4 Antibodies)+ Treg cells, which contribute to the maintenance of immune homeostasis at least partially by splenic CD8alpha+ CD103 (show ITGAE Antibodies)+ dendritic cells
CCL22-specific antibodies reveal that engagement of two distinct binding domains on CCL22 is required for CCR4 (show CCR4 Antibodies)-mediated function.
CCL22 was localised mainly on the cell surface and or in the cytoplasm. Within sections of omental milky spot micrometastases, CCR4 (show CCR4 Antibodies) was recognised on or in gastric cancer cells, constituent cells milky spots, blood cells and blood endothelial cells
results show that the IL-4 (show IL4 Antibodies)/CCL22/CCR4 (show CCR4 Antibodies) axis is involved in the migration of Tregs to osteolytic lesion sites, and attenuates development of lesions by inhibiting inflammatory migration and the production of proinflammatory and osteoclastogenic mediators
CCL22 has a role in Treg skin homing to suppress depigmentation
CCL22 is a novel mediator of lung inflammation following hemorrhage and resuscitation
The immunomodulatory properties of CCL22 could be harnessed for prevention of graft rejection and type 1 diabetes as well as other autoimmune disorders.
Data indicate macrophage-derived chemokine CCL22 as an adjuvant could enhance the immune protective effect of NTHi-P6 protein vaccine to an extent.
islet expression of CCL22 recruits Tregs and attenuates autoimmune destruction of beta cell
This gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for monocytes, dendritic cells, natural killer cells and for chronically activated T lymphocytes. It also displays a mild activity for primary activated T lymphocytes and has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes. The product of this gene binds to chemokine receptor CCR4. This chemokine may play a role in the trafficking of activated T lymphocytes to inflammatory sites and other aspects of activated T lymphocyte physiology.
chemokine (C-C motif) ligand 22
, C-C motif chemokine 22
, CC chemokine STCP-1
, macrophage-derived chemokine
, small inducible cytokine A22
, small inducible cytokine subfamily A (Cys-Cys), member 22
, small-inducible cytokine A22
, stimulated T cell chemotactic protein 1
, stimulated T-cell chemotactic protein 1
, small inducible cytokine subfamily A (Cys-Cys) member 22
, CC chemokine ABCD-1
, SMALL INDUCIBLE CYTOKINE A22 PRECURSOR (CC CHEMOKINE ABCD-1) (ACTIVATED B AND DENDRITIC CELL-DERIVED)
, activated B and dendritic cell-derived
, dendritic cell and B cell derived chemokine
, small inducible cytokine subfamily A, member 22
, small inducible cytokine subfamily A22